Making Breast Cancer Treatment Decisions After Endocrine Therapy A breast cancer survivorship expert shares her top advice for counseling patients on endocrine therapy at the 5-year mark.

Breast cancer survivors reaching the 5-year mark after endocrine therapy face key decisions on next steps. Expert advice helps guide treatment choices & improve long-term outcomes. #TCSC #BreastCancer #CancerSurvivorship #Oncology #EndocrineTherapy #Cancer

www.oncnursingnews.com/view/making-...

Endocrine therapy induces oxidative stress in ER+ breast cancer that sensitizes persister cells to ferroptosis
Cressey, L., Ferridge, L. R. et al.
Paper
Details
#EndocrineTherapy #ERPositiveBreastCancer #FerroptosisResearch

July Issue: Differential Effects of #EndocrineTherapy Type on #QualityOfLife in Older (≥70 Years) Women with Early‑Stage #BreastCancer

rdcu.be/euaFI

Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer PURPOSEAdjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor (ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those with ER-low BC (ER 1%-10%)...

En CA mama en estadío temprano c/rec estrogénico bajo, omisión de la terapia endocrina se asocia con peor supervivencia general, especialmente en enfermedad residual luego de quimioterapia neoadyuvante y con receptor estrogénico 6 a 10% #endocrinetherapy #breastcancer ascopubs.org/doi/abs/10.1...

Dr. Lajos Pusztai shares a presentation on ctDNA monitoring of ER+ HER2- high-risk #breastcancer during adjuvant #endocrinetherapy today at 4:54pm CDT #ASCO25.
meetings.asco.org/2025-asco-an...
@yaleschoolofmed.bsky.social

A large National Cancer Database study reveals endocrine therapy (ET) improves survival in early-stage ER-low (1%-10%) breast cancer, even after chemo.

@ascocancer.bsky.social #JCO @breastcancernow.bsky.social

#Onco404 #Cancer #Kanser #BreastCancer #MemeKanseri #Oncology #EndocrineTherapy

Omission of Endocrine Therapy in Estrogen Receptor–Low, Early-Stage Breast Cancer In a study reported in the Journal of Clinical Oncology, Choong et al looked at whether the omission of endocrine therapy in patients with estrogen receptor–low (1%–10% on immunohistochemistry), early...

Study: Don't Quit HT, There Are Strong Overall Survival (OS) Benefits Shown for HR+ eBC Patients. #powerofhormonetherapy #endocrinetherapy
ascopost.com/news/april-2...

📌 Here's OncoTerm - Word of the Day! 👋

📌 OncoTerm - Günün Kelimesi! 👋

Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.

#Onco404 #Cancer #Kanser #MedSky #OncSky #CancerAwareness #BreastCancer #ProstateCancer #Hormone #EndocrineTherapy #Vocabulary

Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer Despite adjuvant endocrine therapy (ET), recurrence is still a concern for patients with HR+/HER2- early breast cancer (EBC). We assessed recurrence risk in real-world patients with stage II/III HR+/H...

"Results show unmet need remains despite standard-of-care endocrine therapy." Study of note. "This real-world study ... confirms the need for improved treatment options." BC PATIENTS NEED BETTER TREATMENT OPTIONS ASAP! #hormonetherapy #endocrinetherapy
www.thebreastonline.com/article/S096...

Learn more about the CAMBRIA-1 & CAMBRIA-2 phase III trials on #camizestrant versus standard #EndocrineTherapy in ER+/HER2- early #BreastCancer.
🔓https://pubmed.ncbi.nlm.nih.gov/40017004/
✍️@erikahamilton9.bsky.social @michaelgnant.bsky.social
@stolaney1.bsky.social @barbarapistill2.bsky.social

New—overall survival results from Young-PEARL:

#Palbociclib plus #endocrinetherapy versus capecitabine in #premenopausal women with hormone receptor-positive, HER2-negative metastatic #breastcancer

The COMET Randomized Clinical Trial on Active Monitoring With or Without #EndocrineTherapy for Low-Risk #DuctalCarcinomaInSitu was recently published in JAMA, check it out here: pubmed.ncbi.nlm.nih.gov/39665585/

Join Dr. Ann Partridge in the #SABCS24 General Session 2 as she discusses patient-reported outcomes from the COMET Study (AFT-25), comparing active monitoring versus surgery (+/- radiation) with or without #EndocrineTherapy for low-risk #DCIS.